RGD Reference Report - Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.

Authors: Shi, Q  Wang, XS  Li, G  Shah, ND  Orlowski, RZ  Williams, LA  Mendoza, TR  Cleeland, CS 
Citation: Shi Q, etal., Cancer. 2015 Apr 1;121(7):1138-46. doi: 10.1002/cncr.29154. Epub 2014 Dec 2.
RGD ID: 11049156
Pubmed: PMID:25469832   (View Abstract at PubMed)
PMCID: PMC4368488   (View Article at PubMed Central)
DOI: DOI:10.1002/cncr.29154   (Journal Full-text)

BACKGROUND: This study was conducted to determine whether any regulatory single-nucleotide polymorphism (SNP) in an inflammatory gene was associated with a high symptom burden in patients 1 year after the diagnosis of multiple myeloma (MM). METHODS: MM patients rated symptoms with the MD Anderson Symptom Inventory multiple myeloma module (MDASI-MM) and provided buccal-swab DNA samples. SNPs for 4 cytokine genes (interleukin 6 [IL6] -174G>C, IL1beta -511C>T, tumor necrosis factor alpha [TNFalpha] -308G>A, and IL10 -1082G>A) were tested. Logistic regression models were used to identify SNPs that might predict moderate/severe symptoms (rated >/= 4 on the MDASI-MM 0-10 scale). For the evaluation of the relationship between SNPs and overall symptom burden, a 2-step cluster analysis was used to divide patients into subgroups with high or low symptom levels. RESULTS: Forty-one percent of the 344 patients enrolled had a high overall symptom burden. The most prevalent moderate/severe symptoms were fatigue (47%), pain (42%), numbness (38%), and bone aches (32%). For non-Hispanic whites, the IL1beta -511 CC genotype was associated with a high overall symptom burden (odds ratio [OR], 2.35; 95% confidence interval [CI], 1.25-4.72; P = .004), whereas the IL6 -174 GG genotype predicted less moderate/severe fatigue (OR, 0.53; 95% CI, 0.29-0.88; P = .013). For other patients, the IL6 -174 GG genotype predicted moderate/severe pain (OR, 3.36; 95% CI, 1.23-13.64; P = .010). CONCLUSIONS: These results support growing evidence showing that inflammation is associated with cancer-related symptoms, and they suggest that racial/ethnic factors contribute to this association.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
IL1AHumanmultiple myeloma  IAGP DNA:SNP:promoter:-511C>T (human)RGD 
Il1aRatmultiple myeloma  ISOIL1A (Homo sapiens)DNA:SNP:promoter:-511C>T (human)RGD 
Il1aMousemultiple myeloma  ISOIL1A (Homo sapiens)DNA:SNP:promoter:-511C>T (human)RGD 

Phenotype Annotations    Click to see Annotation Detail View

Manual Human Phenotype Annotations - RGD

Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
IL1AHumanMultiple myeloma  IAGP DNA:SNP:promoter:-511C>TRGD 
Objects Annotated

Genes (Rattus norvegicus)
Il1a  (interleukin 1 alpha)

Genes (Mus musculus)
Il1a  (interleukin 1 alpha)

Genes (Homo sapiens)
IL1A  (interleukin 1 alpha)


Additional Information